Thymosin Alpha-1
Thymosin Alpha-1 (Tα1) is a naturally occurring 28-amino acid peptide derived from thymosin fraction 5 of the thymus gland. It is FDA-approved in the US as an orphan drug and approved in 35+ countries (as Zadaxin) for chronic hepatitis B and C, cancer immunotherapy adjunct, DiGeorge syndrome, and severe sepsis. It is a potent thymic hormone that matures naive T-cells, enhances NK cell activity, and restores immune competence in immunocompromised states. Growing use in biohacking/longevity communities for immune optimization, chronic infections, and post-viral syndromes (Long COVID). Extraordinarily safe profile across decades of clinical use.
Evidence
No score yet
Safety
Unknown safety profile
Clinical Status
No formal phase listed
Research Sync
Not synced yet
Dosing
Set height & weight in Settings to see your dose.
Pharmacology
Evidence Score
Plain-English Snapshot
Thymosin Alpha-1 is currently categorized as a peptide compound.
Evidence scoring has not been fully computed yet, so interpret this profile as preliminary.
Safety scoring is incomplete. Start conservatively and monitor carefully.
Core mechanism
TLR2/9 agonism activates dendritic cells; T-cell differentiation (Th1 skew) via IL-12/IFN-γ; NK cell maturation; upregulates MHC class I expression on tumor cells
Practical Context
Strongest current signals
No indexed study summaries yet.